These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 38323514)

  • 1. Lipid-Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Bétrisey S; Haller ML; Efthimiou O; Speierer A; Del Giovane C; Moutzouri E; Blum MR; Aujesky D; Rodondi N; Gencer B
    J Am Heart Assoc; 2024 Feb; 13(4):e030714. PubMed ID: 38323514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials.
    Lee M; Cheng CY; Wu YL; Lee JD; Hsu CY; Ovbiagele B
    JAMA Neurol; 2022 Apr; 79(4):349-358. PubMed ID: 35188949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
    Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Lowering Low-Density Lipoprotein Cholesterol With Contemporary Lipid-Lowering Therapies and Risk of Diabetes Mellitus: A Systematic Review and Meta-Analysis.
    Khan SU; Rahman H; Okunrintemi V; Riaz H; Khan MS; Sattur S; Kaluski E; Lincoff AM; Martin SS; Blaha MJ
    J Am Heart Assoc; 2019 Apr; 8(7):e011581. PubMed ID: 30898075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.
    Marston NA; Giugliano RP; Im K; Silverman MG; O'Donoghue ML; Wiviott SD; Ference BA; Sabatine MS
    Circulation; 2019 Oct; 140(16):1308-1317. PubMed ID: 31530008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.
    Sabatine MS; Wiviott SD; Im K; Murphy SA; Giugliano RP
    JAMA Cardiol; 2018 Sep; 3(9):823-828. PubMed ID: 30073316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
    Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S
    Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR; Knight M
    Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
    Silverman MG; Ference BA; Im K; Wiviott SD; Giugliano RP; Grundy SM; Braunwald E; Sabatine MS
    JAMA; 2016 Sep; 316(12):1289-97. PubMed ID: 27673306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease.
    Paraskevas KI; Gloviczki P; Antignani PL; Comerota AJ; Dardik A; Davies AH; Eckstein HH; Faggioli G; Fernandes E Fernandes J; Fraedrich G; Geroulakos G; Golledge J; Gupta A; Gurevich VS; Jawien A; Jezovnik MK; Kakkos SK; Knoflach M; Lanza G; Liapis CD; Loftus IM; Mansilha A; Nicolaides AN; Pini R; Poredos P; Proczka RM; Ricco JB; Rundek T; Saba L; Schlachetzki F; Silvestrini M; Spinelli F; Stilo F; Suri JS; Svetlikov AV; Zeebregts CJ; Chaturvedi S; Veith FJ; Mikhailidis DP
    Prog Cardiovasc Dis; 2022; 73():41-47. PubMed ID: 35605696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials.
    Gencer B; Marston NA; Im K; Cannon CP; Sever P; Keech A; Braunwald E; Giugliano RP; Sabatine MS
    Lancet; 2020 Nov; 396(10263):1637-1643. PubMed ID: 33186535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Lowering Low-Density Lipoprotein Cholesterol with Contemporary Lipid-Lowering Medicines on Cognitive Function: A Systematic Review and Meta-Analysis.
    Ying H; Wang J; Shen Z; Wang M; Zhou B
    Cardiovasc Drugs Ther; 2021 Feb; 35(1):153-166. PubMed ID: 32770521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of C-reactive protein, low-density lipoprotein cholesterol, and its relationship with cardiovascular events of different lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials.
    Yang W; Cai X; Lin C; Lv F; Zhu X; Han X; Ji L
    Medicine (Baltimore); 2022 Sep; 101(37):e30563. PubMed ID: 36123891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Under-representation of ethnic and regional minorities in lipid-lowering randomized clinical trials: a systematic review and meta-analysis.
    Sawant S; Wang N
    Eur J Prev Cardiol; 2023 Aug; 30(11):1120-1131. PubMed ID: 36748994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol.
    Toth PP; Bray S; Villa G; Palagashvili T; Sattar N; Stroes ESG; Worth GM
    J Am Heart Assoc; 2022 Sep; 11(18):e025551. PubMed ID: 36073669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
    Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.
    Khan SU; Yedlapati SH; Lone AN; Hao Q; Guyatt G; Delvaux N; Bekkering GET; Vandvik PO; Riaz IB; Li S; Aertgeerts B; Rodondi N
    BMJ; 2022 May; 377():e069116. PubMed ID: 35508321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More- Versus Less-Intensive Lipid-Lowering Therapy.
    Toyota T; Morimoto T; Yamashita Y; Shiomi H; Kato T; Makiyama T; Nakagawa Y; Saito N; Shizuta S; Ono K; Kimura T
    Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005460. PubMed ID: 31412729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.